Best Up-Front Treatment for Newly Diagnosed MM - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Best Up-Front Treatment for Newly Diagnosed Myeloma and What to Consider at Relapse with Dr. Andrzej Jakubowiak, MD, PhD

Best Up-Front Treatment for Newly Diagnosed Myeloma and What to Consider at Relapse with Dr. Andrzej Jakubowiak, MD, PhD image

Best Up-Front Treatment for Newly Diagnosed Myeloma and What to Consider at Relapse with Dr. Andrzej Jakubowiak, MD, PhD

Podcast
event Oct 19, 2016 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Andrzej Jakubowiak, MD, PhD University of Chicago Interview Date: October 19, 2016 

Newly diagnosed multiple myeloma is the most sensitive to treatment, so picking the best up-front treatment is key to getting long-term optimal outcomes. Dr. Andrzej Jakubowiak, MD, PhD shares his experience for newly diagnosed patients. He highly suggests triple combinations before stem cell transplants vs. doublet combinations. He is impressed with the Kyprolis, Revlimid, dex triple combination, especially for patients without heart conditions. He also likes the Velcade, Revlimid, dex triple combination for patients without peripheral neuropathy. With more significant disease reduction and patient responses, Dr. Jakubowiak shares that we can now use more sensitive testing (minimal residual disease testing) to help identify which treatments are and are not working at earlier phases of clinical trials. He also suggests that they may become end points worth measuring during these studies. He notes that patients with minimal disease negativity do typically have longer lasting outcomes, but patients with some minimal residual disease can still have good outcomes. To further test the impact of MRD status, he is running a unique trial post transplant that compares Revlimid alone to Ixazomib, Revlimid and dexamethasone (an all oral combination). He stresses that good risk patients benefit from more aggressive myeloma treatment up front and says that this theme is moving its way into the clinic for high-risk smoldering myeloma patients. Dr. Jakubowiak shares a variety of strategies that can be used at relapse, depending on the kind of relapse and options previously used.

multiple myeloma

Thanks to our episode sponsor

Schedule & Agenda

Event panelist  Dr. Andrezej Jakubowiak & Jenny Ahlstrom
11:00 AM
Discussion
Dr. Andrezej Jakubowiak & Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Large Granular Lymphocytic Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.